Efgartigimod Alfa as a novel rescue therapy for severe NMOSD: a case report
Authors:
- 25 March 2026
- journal article
- letter
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (4) , 369
Abstract
No abstract availableKeywords
Funding Information
- the third batch of Zhao Yang talent Cultivation Project of Affiliated Hosptial of Shandong University of Traditional Chinese Medicine (zyrc-2024-43)
This publication has 12 references indexed in Scilit:
- Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disordersOrphanet Journal of Rare Diseases, 2024
- Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: A Case ReportHeliyon, 2024
- A comprehensive review of the advances in neuromyelitis optica spectrum disorderAutoimmunity Reviews, 2023
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term managementJournal of Neurology, 2023
- Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its UseCNS Drugs, 2023
- The therapeutic age of the neonatal Fc receptorNature Reviews Immunology, 2023
- Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSDCNS Neuroscience & Therapeutics, 2022
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2021
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansJournal of Clinical Investigation, 2018
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015